Entity

Time filter

Source Type

Ymittos Athens, Greece

Mountzios G.,251 Air Force General Hospital | Mountzios G.,National and Kapodistrian University of Athens | Pectasides D.,National and Kapodistrian University of Athens | Pectasides E.,National and Kapodistrian University of Athens | And 2 more authors.
Forum of Clinical Oncology | Year: 2013

Despite the available prevention and early detection strategies, squamous-cell carcinoma of the uterine cervix is still diagnosed as locally advanced disease in a large proportion of patients. Treatment with cisplatin, in combination with external beam irradiation, has been the cornerstone of treatment in this setting for more than two decades. Induction chemotherapy strategies followed by concurrent chemo-radiation or surgery and pre-operative concurrent chemo-radiation have been recently implemented in clinical trials in an effort to optimize both local control and the occurrence of distant metastases. More recently, combinations of chemotherapy or radiotherapy with molecular agents targeting critical pathways in cervical malignant transformation are being assessed in clinical trials. In this paper, we review the role of cisplatin in the disease in the context of other potent radiosensitizers. We also discuss all recently implemented therapeutic modalities for the treatment of locally advanced cervical cancer with emphasis on the novel induction strategies. Concerns regarding treatment-related toxicity in the context of co-morbidities and the need for potent predictive biomarkers for individualized therapeutic approach are also addressed. Source


Poukoulidou T.,National and Kapodistrian University of Athens | Spyridaki A.,National and Kapodistrian University of Athens | Mihailidou I.,National and Kapodistrian University of Athens | Kopterides P.,National and Kapodistrian University of Athens | And 15 more authors.
BMC Infectious Diseases | Year: 2011

Background: Current knowledge on the exact ligand causing expression of TREM-1 on neutrophils and monocytes is limited. The present study aimed at the role of underlying infection and of the causative pathogen in the expression of TREM-1 in sepsis.Methods: Peripheral venous blood was sampled from 125 patients with sepsis and 88 with severe sepsis/septic shock. The causative pathogen was isolated in 91 patients. Patients were suffering from acute pyelonephritis, community-acquired pneumonia (CAP), intra-abdominal infections (IAIs), primary bacteremia and ventilator-associated pneumonia or hospital-acquired pneumonia (VAP/HAP). Blood monocytes and neutrophils were isolated. Flow cytometry was used to estimate the TREM-1 expression from septic patients.Results: Within patients bearing intrabdominal infections, expression of TREM-1 was significantly lower on neutrophils and on monocytes at severe sepsis/shock than at sepsis. That was also the case for severe sepsis/shock developed in the field of VAP/HAP. Among patients who suffered infections by Gram-negative community-acquired pathogens or among patients who suffered polymicrobial infections, expression of TREM-1 on monocytes was significantly lower at the stage of severe sepsis/shock than at the stage of sepsis.Conclusions: Decrease of the expression of TREM-1 on the membrane of monocytes and neutrophils upon transition from sepsis to severe sepsis/septic shock depends on the underlying type of infection and the causative pathogen. © 2011 Poukoulidou et al; licensee BioMed Central Ltd. Source


Kotsakis A.,University General Hospital of Heraklion | Kotsakis A.,University of Crete | Papadimitraki E.,University General Hospital of Heraklion | Papadimitraki E.,University of Crete | And 9 more authors.
Lung Cancer | Year: 2014

Objectives: The immunological and clinical responses of patients with NSCLC treated, in the context of an expanded action program, with the cryptic hTERT-targeting Vx-001 vaccine are presented. Materials and methods: Forty-six HLA-A*0201-positive patients with advanced NSCLC and residual (n=27) or progressive (n=19) disease following front-line treatment received two subcutaneous injections of the optimized TERT572Y peptide followed by four injections of the native TERT572 peptide, every 3 weeks. Peptide-specific immune responses were monitored by enzyme-linked immunosorbent spot assay at baseline, and after the 2nd and the 6th vaccinations. Thirty-eight HLA-A*0201-positive matched patients were used as historical controls. Results: Twenty-three patients (50%) completed the vaccination protocol and 87% received at least two administrations. Twelve patients (26%) without disease progression after the 6th vaccination received boost vaccinations. Three (7%) patients achieved a partial response and 13 (28%) disease stabilization. The disease control rate was significantly higher in patients with non-squamous histology compared to those with squamous-cell histology [. n= 14 (45%) versus n= 2 (13%); p= 0.03]. The median progression-free survival (PFS) and overall survival (OS) was 3.8 (range, 0.7-99.4) and 19.8 months (range, 0.7-99.4), respectively. Patients who developed immune response had a numerically higher PFS compared to those who failed to mount any (6.7 versus 2.7 months; p= 0.090). However, the median OS for the immune-responders was significantly prolonged compared to non-responders (40.0 versus 9.2 months, respectively; p= 0.02). Toxicity was Source


Kourgiannidis G.,251 Air Force General Hospital | Anastasakis A.,National and Kapodistrian University of Athens | Lampropoulos K.,251 Air Force General Hospital | Iliopoulos T.,251 Air Force General Hospital
Hellenic Journal of Cardiology | Year: 2013

Lamin A/C is a major constituent of the nuclear lamina, the proteinaceous meshwork underlying the inner nuclear membrane. Laminopathies are a group of diseases with heterogeneous clinical presentation. Lamin A/C mutations are a well-established cause of dilated cardiomyopathy. In our case, a novel mutation of lamin A/C presented in the typical form of cardiolaminopathy with ventricular tachycardia and mild myocardial dysfunction in an apparently healthy, middle-aged individual. Source


Kassi E.N.,National and Kapodistrian University of Athens | Stavropoulos S.,National and Kapodistrian University of Athens | Kokkoris P.,251 Air Force General Hospital | Galanos A.,National and Kapodistrian University of Athens | And 5 more authors.
Hormones | Year: 2015

OBJECTIVE: We aimed to determine the prevalence of 25(OH)D (D2 and D3 independently) inadequacy in healthy young/middle-aged men and to investigate its relationship with BMD, bone markers, demographic and lifestyle parameters such as age, BMI, smoking, alcohol consumption and dietary calcium intake. DESIGN: We determined 25(OH)D levels using LC-MS/ MS, a robust method for measurement of both 25(OH)D3 and 25(OH)D2, iPTH, osteocalcin, beta C terminal cross-linked telopeptides of type I collagen (b-CTXs), procollagen type 1 aminoterminal propeptide (PINP), BMD at L2-L4 and proximal femur, smoking habits, daily dietary calcium intake and alcohol consumption in 181 randomly selected healthy men aged 20-50y. RESULTS : The prevalence of vitamin D deficiency (25(OH)D <20ng/ml) was 50.3%. Only 8.8% of the participants had vitamin D sufficiency (25(OH)D ≥30ng/ml). We found a strong correlation between 25(OH)D and smoking in the totality of participants (p<0.001). 25(OH)D level was lower by approximately 4.3 ng/dl (p<0.001) in a smoker compared to a non-smoker among the totality of participants, while this value increased to 9.2ng/ml in the 40-50y subgroup (p=0.003). A multinomial logistic regression model demonstrated that a young smoker (20-29y) had 58% increased likelihood of having vitamin D deficiency compared to a non-smoker of the same age group (p=0.041). CONCLUSIONS: A high prevalence of vitamin D deficiency was identified in a young and middle-aged male population. Smoking is a significant determinant of serum 25(OH)D, while it increases significantly the likelihood of having vitamin D deficiency. In our hands, vitamin D levels are not a determinant of bone turnover and BMD in this population. © 2015, Hellenic Endocrine Society. All rights reserved. Source

Discover hidden collaborations